All In Biotech

Drug Trial Radar · NCT06898450

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair

Last checked: Nov 20, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

134

Planned (sponsor's estimate)

Start

Mar 31, 2025

Primary completion

Oct 2031

Study completion Dec 2031

Sponsor

Lead sponsor
Nimbus Wadjet, Inc.Industry
Sponsor type
Industry
Collaborators
Worldwide Clinical Trials
First posted
Mar 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main questions it aims to answer are: Is NDI-219216 safe and what kinds of side effects might it cause? What kind of effects does NDI-219216 have on the body? Does NDI-219216 have any impact on tumor size? Participants will: Take NDI-219216 every day by mouth. Visit the clinic 6 times during Cycle 1, 2 times during Cycle 2, once a month thereafter for checkups and tests while on the study, then one time for an end of treatment visit. After the End of Study, a follow up will occur but can be done on the phone. Keep a diary of their tablet consumption and symptoms experienced.

Conditions

  • Advanced Solid Tumors Cancer
  • MSI-H Cancer

Interventions

  • NDI-219216Drug

    NDI-219216 is a highly selective small molecule inhibitor of WRN helicase activity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A Primary Objective: Incidence of dose limiting toxicities (DLTs)Time frame: The first 21 days of Cycle 1 (Cycle 1 is 28 days).
  2. Part A Primary Outcome: • Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), according to NCI CTCAE v5.0Time frame: From first dose of study drug until 30 days after last dose of study drug; up to approximately 11-12 months. Each Cycle is 28 days.
  3. Part A Primary Outcome: Incidence and severity of Treatment Emergent Adverse Events (TEAEs) and Treatment Related Adverse Events (TRAEs) as assessed by the InvestigatorTime frame: From first dose of study drug until 30 days after last dose of study drug; up to approximately 11-12 months. Each Cycle is 28 days.
  4. Part B Primary Objective: Overall Response Rate (ORR) per RECIST v1.1.Time frame: From start of study treatment until end of follow-up, up to approximately 18 months. Each Cycle is 28 days.
  5. Part B Primary Outcome: Duration of Response (DOR) per RECIST v1.1Time frame: From the time of first occurrence of a documented response until the time of documented disease progression or death from any cause, whichever occurs first; up to approximately 18 months. Each Cycle is 28 days.
  6. Part B Primary Outcome: Incidence and severity of AEs according to NCI CTCAE v5.0.Time frame: From first dose of study drug until 30 days after last dose of study drug; up to approximately 18 months. Each Cycle is 28 days.
  7. Part C Primary Objective: Overall Response Rate (ORR) per RECIST v1.1.Time frame: From start of study treatment until end of follow-up, up to approximately 17 months. Each Cycle is 28 days.
  8. Part C Primary Outcome: Duration of Response (DOR) per RECIST v1.1.Time frame: From the time of first occurrence of a documented response until the time of documented disease progression or death from any cause, whichever occurs first, up to approximately 17 months. Each Cycle is 28 days.

Locations

22 sites in 8 countries. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • University of Chicago Medicine

    Chicago, Illinois · Recruiting

  • University of Louisville James Graham Brown Cancer Center

    Louisville, Kentucky · Recruiting

  • Cayuga Cancer Center

    Ithaca, New York · Terminated

  • Levine Cancer Center

    Charlotte, North Carolina · Recruiting

  • Atrium Health Wake Forest Baptist Center

    Winston-Salem, North Carolina · Recruiting

  • Taylor Cancer Research Center

    Maumee, Ohio · Recruiting

  • Brown University Health

    Providence, Rhode Island · Recruiting

  • Prisma Health Cancer Institute - Multidisciplinary Center

    Greenville, South Carolina · Recruiting

  • University of Virginia Emily Couric Clinical Cancer Center

    Charlottesville, Virginia · Recruiting

  • Virginia Cancer Specialists, P.C. - Fairfax

    Fairfax, Virginia · Recruiting

  • Liverpool Hospital

    Liverpool, New South Wales, Australia · Recruiting

  • Southern Oncology Clinical Research Unit

    Bedford Park, South Australia, Australia · Recruiting

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada · Recruiting

  • Hôpital Saint-Antoine - Assistance Publique-Hopitaux de Paris (AP-HP)

    Paris, France · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Poitiers

    Poitiers, France · Recruiting

  • START Dublin

    Dublin, Ireland · Recruiting

  • START Lisbon

    Lisbon, Portugal · Recruiting

  • START Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Clinico San Carlos

    Madrid, Spain · Recruiting

  • Sarah Cannon Research Institute UK

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust UK

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.